arrow
C

Chor Sang Chim

comprehensive oncology centre
H指数:51
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)

随机化III期研究:比较泊马利度胺联合环磷酰胺、地塞米松与泊马利度胺联合地塞米松治疗复发或难治性骨髓瘤的疗效——一项亚洲骨髓瘤网络研究(AMN003)

2025-10-060
OA
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study (Sept, 10.1007/s00277-024-05958-8, 2024)
2024-09-230
OAAI
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
2024-09-041
OAAI
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
2020-02-2924
OAAI
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
2019-10-0811
OAAI